NCT07446322 FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer Status RECRUITING Phase PHASE2
NCT07323576 A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer Status WITHDRAWN Phase PHASE2
NCT07318389 ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer Status NOT_YET_RECRUITING Phase EARLY_PHASE1
NCT07221357 A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer Status RECRUITING Phase PHASE2/PHASE3
NCT07021950 AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT06747845 Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy Status RECRUITING Phase PHASE2
NCT06663319 A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers Status RECRUITING Phase PHASE1
NCT06179160 A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation Status RECRUITING Phase PHASE1
NCT06106308 Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05879055 A Study of PM8002 in Combination With Chemotherapy in Patients With NEN Status RECRUITING Phase PHASE2
NCT05836324 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Status RECRUITING Phase PHASE1
NCT05786924 Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies Status RECRUITING Phase PHASE1/PHASE2
NCT05684211 A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer Status UNKNOWN Phase PHASE2
NCT05634590 The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT05593328 Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation Status COMPLETED Phase PHASE2
NCT05362617 mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy Status UNKNOWN Phase PHASE3
NCT05312398 CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen Status ACTIVE_NOT_RECRUITING Phase PHASE2